THE TRUMP ADMINISTRATION: MedPage Today: AAP Disputes Kennedy's Claim That Vaccine Panel Can't Meet Ahead Of Flu Season ++++++

THE TRUMP ADMINISTRATION MedPage Today: AAP Disputes Kennedy's Claim That Vaccine Panel Can't Meet Ahead Of Flu Season The American Academy of Pediatrics (AAP) pushed back on HHS Secretary Robert F. Kennedy Jr.'s claims that the CDC's vaccine panel is unable to meet due to a recent ruling in a lawsuit challenging changes to the U.S. childhood immunization schedule. On June 12, Kennedy took to X to announce the filing of a motion asking the First Circuit Court of Appeals to expedite an appeal of the district court's order that he contended left the Advisory Committee on Immunization Practices (ACIP) "without a quorum." The AAP rebuffed this claim. (Henderson, 6/16) https://www.medpagetoday.com/publichealthpolicy/washington-watch/121790?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz--yF_fbEObO4EA7YFj_u0fTlze18Ve5uTE8tv1NEhSNCz7lFk34ASIdhjQbdcb9f9v8658v8q27k8bvRFhQSBMZ1sDWKw&_hsmi=424219119&utm_content=424219119&utm_source=hs_email MedPage Today: Experts Pan RFK Jr.'s Inquiry Into Removal Of Flawed Vaccine Study Legal and public health experts expressed concern about HHS Secretary Robert F. Kennedy Jr.'s scrutiny of a medical journal's decision to remove a study that purportedly suggested an increased incidence of sudden infant death syndrome (SIDS) within a few days after vaccination. (Frieden, 6/16) https://www.medpagetoday.com/pediatrics/vaccines/121793?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz--PMQGQRpm5X1sYXwNdiOQ0LuyiGBDOrgjhpkcjXzilIOa1scAz3fiuaw9R5HGDm1cSPnHRKFgElTkgVIhF6oRP1gno-w&_hsmi=424219119&utm_content=424219119&utm_source=hs_email The 19th: Bill Targets Insurance Gap For Cancer Survivors Who Can’t Breastfeed Erika Nyhus thought she was done having children. The mother of two had required medical intervention to become pregnant in the past, and she’d been told that the breast cancer treatment she’d completed would further diminish her fertility. Then two-and-a-half years ago, feeling rundown after returning home from a family trip, she took a pregnancy test out of an abundance of caution. She assumed it would be negative. (Luthra, 6/16) https://19thnews.org/2026/06/breastfeeding-formula-cancer-survivors-insurance-coverage/?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz-87sTlDSpVGOXCSVY-XkyBRcG0B0hj3CkuIxn67crfpxQqccfps3gVlOaxX6oJNoJs-M0mVqRVStrE-Q2yRMkJATLaiGQ&_hsmi=424219119&utm_content=424219119&utm_source=hs_email The Hill: NIH Launches New Office To Reduce Animal Testing The National Institutes of Health (NIH) on Monday announced the launch of a new office aimed at reducing the use of animal-based research testing and boosting the use of testing methods that “better reflect human biology.” NIH’s new office will be named the Office of Research Innovation, Validation, and Application (ORIVA). Reducing animal testing has been among the primary goals within the Department of Health and Human Services (HHS) under Secretary Robert F. Kennedy Jr.’s tenure. (Choi, 6/16) https://thehill.com/policy/healthcare/5926556-nih-launches-office-reduce-animal-testing/?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz-952K2QVvFz2mic0XMzQ98QXK0xgVOSp_6jSUldCa1CMZl5oB9ii87gpLJFege9Cke9-gzNFB4Dfey67ek2CxpEm_iiEQ&_hsmi=424219119&utm_content=424219119&utm_source=hs_email The Hill: FDA Approves Third OTC Naloxone Nasal Spray For Opioid Overdose The Food and Drug Administration (FDA) approved a third over-the-counter version of naloxone nasal spray Tuesday, in a move the agency said could save lives and reduce costs. The agency approved another Rextovy, a 4 milligram naloxone nasal spray for the emergency treatment of opioid overdose. FDA said consumers may directly buy it in pharmacies, convenience stores and online. Naloxone is a medicine that can help reduce opioid overdose deaths and when administered in time, usually within minutes of the first signs of an opioid overdose, can counter the overdose effects. (Weixel, 6/16) https://thehill.com/policy/healthcare/5927054-fda-naloxone-nasal-spray-rextovy/?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz--kmiXeh4DX-aVZAeOGKDudbMO8un5jXVly2DNS000LPeLGRXjX0lN9x8sRjhkFn9SRNMmehlC2DYWdLOvFPb4OfNV7KQ&_hsmi=424219119&utm_content=424219119&utm_source=hs_email MedPage Today: FDA Staff Weigh In On Potential First MRNA Flu Shot Ahead of an advisory committee meeting this week, FDA reviewers raised no serious efficacy or safety concerns about Moderna's mRNA flu vaccine candidate for adults 50 and older, which has the potential to become the first such product approved by the agency. (Rudd, 6/16) https://www.medpagetoday.com/infectiousdisease/uritheflu/121795?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz-9qPCOir0U5yW_miQJ25hnRW_K3iE5Wk6Okepp6bOl-bGTgFJTe4ySVBkPCOiNx92FxVxdUrKmMicyEHXWGGig1bmC-gw&_hsmi=424219119&utm_content=424219119&utm_source=hs_email